US equities |
SPCX $166.96 ▲+5.03% NVDA $236.80 ▲+1.22% MU $1,064.35 ▼-0.98% TSLA $377.10 ▲+1.76% MSFT $526.52 ▲+1.74% SNDK $1,714.58 ▼-0.31% INTC $117.43 ▼-1.59% META $744.61 ▲+2.27%
FinancialContent

Articles published by Oragenics, Inc.

News headline image
Oragenics Q3 2025 Shareholder Update
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics, Inc. Files 10K and Provides Company Update
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Announces Closing of Public Offering
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Announces Pricing of Public Offering
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Announces Proposed Public Offering
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics, Inc. Announces Leadership Transition
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Announces Termination of At-The-Market Offering Program
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
From Oragenics, Inc.
Via Business Wire
Tickers ODYY OGEN
News headline image
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics, Inc. Announces Private Placement
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics to Participate in the World Vaccine Congress Washington
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics, Inc. Regains Compliance with NYSE American
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics, Inc. Receives NYSE American Notice
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics, Inc. Announces New Chair
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics to Participate in the 2022 BioFlorida Annual Conference
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
News headline image
Oragenics Issues Letter to Shareholders
From Oragenics, Inc.
Via Business Wire
Tickers OGEN